Lv51
1210 积分 2024-04-22 加入
Type I IFN system in the development and manifestations of SLE
15天前
已完结
Analysis of phase II and phase III clinical trial terminations from 2013 to 2023
15天前
已关闭
Analysis of phase II and phase III clinical trial terminations from 2013 to 2023
17天前
已关闭
The present and future of bispecific antibodies for cancer therapy
17天前
已完结
Turning cold into hot: emerging strategies to fire up the tumor microenvironment
18天前
已完结
Analysis of phase II and phase III clinical trial terminations from 2013 to 2023
18天前
已关闭
Trends in target novelty in oncology R&D
21天前
已完结
Antibody-lectin chimeras for glyco-immune checkpoint blockade
21天前
已完结
Trends in target novelty in oncology R&D
21天前
已关闭
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
1个月前
已完结
皖公网安备34019202002308
